



Docket No.: 205907US0PCT

RECEIVED
JAN 07 2003
TECH CENTER 1600/2900



ATTORNEYS AT LAW

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RE: Application Serial No.: 09/830,669

Applicants: Philippe MARLIERE, et al.

Filing Date: April 30, 2001

For: PROCESS FOR PRODUCING CHEMICALLY
DIVERSIFIED PROTEINS, IN VIVO, BY
INCORPORATING UNCONVENTIONAL AMINO
ACIDS

Group Art Unit: 1636

Examiner: Gerald G. Leffers, Jr.

SIR:

Attached hereto for filing are the following papers:

Response to Notice (3 pp.)

Copy of Sequence Listing Computer Readable Form (CRF) Diskette Filed January 16, 2002

Copy of Preliminary Amendment Filed January 16, 2002

Copy of Sequence Listing Paper Filed January 16, 2002


Copy of Date-Stamped Filing Receipt Dated January 16, 2002

Return Copy - Notice to Comply

Our check in the amount of **\$0.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618




22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Thomas W. Barnes III, Ph.D.
Registration No. 252,595

1755 JEFFERSON DAVIS HIGHWAY ■ FOURTH FLOOR ■ ARLINGTON, VIRGINIA 22202 ■ U.S.A.
TELEPHONE: 703-413-3000 ■ FACSIMILE: 703-413-2220 ■ WWW.OBLON.COM



Notice to Comply

Application No.	Applicant(s)
09/830,669	MARLIERE ET AL.
Examiner	Art Unit
Gerald G. Leffers Jr.	1636

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: There are sequences in the specification that lack sequence identifiers. The amendment to the specification to provide sequence identifiers filed 16 Jan 2002 has not been entered as the amendments were not made as per USPTO practice (see the attached sheet). In short, the indicated paragraphs were not paragraphs in themselves, but were actually part of larger paragraphs. It would be remedial to re-submit the amendment with the entire paragraph indicated for replacement. There is no need for additional copies of the sequence listing.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED
JAN 07 2003
TECH CENTER 1600/2900



RECEIVED

JAN 07 2003

TECH CENTER 1600/2900

Dept.: CHEMICAL

By: NFO:DJP:TWB:aps

OSMM&N File No. 205907US0PCT

Serial No. 09/830,669

In the matter of the Application of: Philippe MARLIERE, et al.

For: METHOD FOR PRODUCING IN VIVO PROTEINS CHEMICALLY DIVERSIFIED BY INCORPORATING NON-STANDARD AMINO ACIDS

The following has been received in the U.S. Patent Office on the date stamped hereon:

<input type="checkbox"/> pp. Specification	Claims/Formal Drawings	Sheets
and pages Application Data Sheet		
<input type="checkbox"/> Combined Declaration, Petition & Power of Attorney	pages	
<input type="checkbox"/> List of Inventor Names and Addresses		
<input type="checkbox"/> Utility Patent Application Transmittal	□ CPA	
<input type="checkbox"/> Notice of Priority	□ Priority Doc	
<input type="checkbox"/> Check for	■ Dep. Acct. Order Form	
<input type="checkbox"/> Fee Transmittal Form		
<input type="checkbox"/> Assignment/PTO 1595 pages:		
<input type="checkbox"/> Letter to Official Draftsman		
<input type="checkbox"/> Letter Requesting Approval of Drawing Changes		
<input type="checkbox"/> Formal Drawings sheets	<input type="checkbox"/> Formal	
<input checked="" type="checkbox"/> PTO Cover Letter		
<input checked="" type="checkbox"/> Amendment w/Marked-Up Copy (4 pp.)		
<input type="checkbox"/> Information Disclosure Statement	□ PTO-1449	
<input checked="" type="checkbox"/> Sequence Listing Paper (3 pp.)		
<input checked="" type="checkbox"/> Sequence Listing Computer Readable Form (CRF) Diskette		
<input type="checkbox"/> Statement of Relevancy	□ Cited Pending Applications	
<input type="checkbox"/> IDS/Related/List of Related Cases		
<input type="checkbox"/> Restriction Response	□ Election Response	
<input type="checkbox"/> Rule 132 Declaration		
<input type="checkbox"/> Request for Extension of Time		
<input type="checkbox"/> Notice of Appeal		
<input type="checkbox"/> Issue Fee Transmittal		
<input type="checkbox"/> White Advance Serial Number Card		
<input type="checkbox"/> Small Entity Status is Claimed		
<input checked="" type="checkbox"/> Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office DO/EO/US)		
<input type="checkbox"/>	Due Date: January 16, 2002	

